$RLFTF DD (opinion) by f on Yh0: Ingenious who thought to buy out APR.
Translation APR Test @ Max
Covid, here's the nasal spray made in Italy. "Deleted Sars-Cov-2 in less than one minute in laboratory tests"
The idea of a nasal coronavirus spray has already had some initial positive feedback in Israel and the UK.
The first human tests for nasal spray in the San Martino Hospital in Genoa have now started in Italy. Patient recruitment will begin on 15 May.
The test will test the safety and efficacy of the spray (AOS2020), inhaled in both nostrils three and a half times a day, in reducing the viral load in the high respiratory tract.
This figure, when available, will be the starting point for the use of the product in preventing the most severe symptoms and in reducing human contagion and the spread of the virus.
The clinical trial is conducted by the Hygiene Unit of the Genoa Polyclinic and coordinated by Giancarlo Icardi.
The clinical trial will enlist a total of 57 Infected Covid-19, Buffer-Positive Patients with Slight Symptoms.
f
Inquiring minds want to know.
The article is saying that the first results are expected within four months and, if positive, the product will be available by the end of the year. Spray is an aqueous washing solution containing 0.005% hypochlorous acid, an antimicrobial substance also produced by the cells of our immune system, which has been made stable and pure and therefore inhalable by Tehclo*, a nanotechnology designed and developed by a team of Italians from the Italian-Swiss company Apr Applied Pharma Research s.a., which patented technological innovation.
The results of the in vitro and in vivo preliminary tests, recently published in the Official Journal of the European Society of Otorinolaringoiatria, showed, in a note, that the nasal spray based on hypochlorous acid eliminates Sars-Cov-2 in less than a minute without irritating the mucous membranes of the nose and throat.
The nasal spray, which will be produced in Italy, could in future also provide additional protection to prevent the spread of contagion, especially in high - risk environments such as public transport or schools.
The strong anti-microbial action of this substance is well known, but it has not been exploitable in this way until now, as it is inhalable because it is harmful to humans. The new nanotechnology, developed by a team of Italians, has made it inhalable without irritating the mucous membranes of nose and throat.
The conservation of the solution does not require particular precautions and can be maintained for two years at room temperature of 5 to 25 degrees C.
The new technology has been designed and developed - a note reads - to the team of Paolo Galfetti, Roberto De Noni and Giorgio Reiner of the Italian-Swiss company Apr. Similar products from the same technology have already been certified as Class 3 medical devices and have already been widely used for several years In Italy, the United States and England, with other indications.
Several in vitro and in vivo safety tests have been carried out in recent years by the company, in addition to the human clinical practice, confirming an excellent safety profile of the solution in different human tissues and up to 20 times lower cytotoxicity than other commercially available antimicrobial solutions.
"On this encouraging premise, a randomized, monocentric and controlled clinical trial was designed to assess whether the spray solution, used to irrigate, hydrate and clean nasal mucous membranes three or five times a day at regular intervals, is safe and effective in Sars-Cov-2 positive patients with few symptoms, in addition to standard therapies, to reduce the viral load in the nose," explains Giancarlo by, the Hygiene Unit of the San Martino de Genoa, responsible for the trial.
‘Reducing the amount of virus present in the nose, either by mechanical washing or by antimicrobial efficacy of hypochlorous acid, could reduce patient contagion, prevent the occurrence of more severe symptoms and improve the course of the disease at an early stage, also reducing the likelihood of virus transmission to other persons’.
"If Sars-Cov-2 is less present in the upper respiratory tract, the likelihood of it falling down the lower airways and damaging the lungs, as well as the risk of local injury to the olfactory nerve routes, which is responsible for the loss of the smell related to Covid-19, is reduced.
The spray, if used at the initial stages of the infection or in the event of exposure to the risk of infection, could therefore reduce the likelihood of contagion, clinical deterioration and transmissibility of the infection.’
Translation APR Test @ Max
Covid, here's the nasal spray made in Italy. "Deleted Sars-Cov-2 in less than one minute in laboratory tests"
The idea of a nasal coronavirus spray has already had some initial positive feedback in Israel and the UK.
The first human tests for nasal spray in the San Martino Hospital in Genoa have now started in Italy. Patient recruitment will begin on 15 May.
The test will test the safety and efficacy of the spray (AOS2020), inhaled in both nostrils three and a half times a day, in reducing the viral load in the high respiratory tract.
This figure, when available, will be the starting point for the use of the product in preventing the most severe symptoms and in reducing human contagion and the spread of the virus.
The clinical trial is conducted by the Hygiene Unit of the Genoa Polyclinic and coordinated by Giancarlo Icardi.
The clinical trial will enlist a total of 57 Infected Covid-19, Buffer-Positive Patients with Slight Symptoms.
f
Inquiring minds want to know.
The article is saying that the first results are expected within four months and, if positive, the product will be available by the end of the year. Spray is an aqueous washing solution containing 0.005% hypochlorous acid, an antimicrobial substance also produced by the cells of our immune system, which has been made stable and pure and therefore inhalable by Tehclo*, a nanotechnology designed and developed by a team of Italians from the Italian-Swiss company Apr Applied Pharma Research s.a., which patented technological innovation.
The results of the in vitro and in vivo preliminary tests, recently published in the Official Journal of the European Society of Otorinolaringoiatria, showed, in a note, that the nasal spray based on hypochlorous acid eliminates Sars-Cov-2 in less than a minute without irritating the mucous membranes of the nose and throat.
The nasal spray, which will be produced in Italy, could in future also provide additional protection to prevent the spread of contagion, especially in high - risk environments such as public transport or schools.
The strong anti-microbial action of this substance is well known, but it has not been exploitable in this way until now, as it is inhalable because it is harmful to humans. The new nanotechnology, developed by a team of Italians, has made it inhalable without irritating the mucous membranes of nose and throat.
The conservation of the solution does not require particular precautions and can be maintained for two years at room temperature of 5 to 25 degrees C.
The new technology has been designed and developed - a note reads - to the team of Paolo Galfetti, Roberto De Noni and Giorgio Reiner of the Italian-Swiss company Apr. Similar products from the same technology have already been certified as Class 3 medical devices and have already been widely used for several years In Italy, the United States and England, with other indications.
Several in vitro and in vivo safety tests have been carried out in recent years by the company, in addition to the human clinical practice, confirming an excellent safety profile of the solution in different human tissues and up to 20 times lower cytotoxicity than other commercially available antimicrobial solutions.
"On this encouraging premise, a randomized, monocentric and controlled clinical trial was designed to assess whether the spray solution, used to irrigate, hydrate and clean nasal mucous membranes three or five times a day at regular intervals, is safe and effective in Sars-Cov-2 positive patients with few symptoms, in addition to standard therapies, to reduce the viral load in the nose," explains Giancarlo by, the Hygiene Unit of the San Martino de Genoa, responsible for the trial.
‘Reducing the amount of virus present in the nose, either by mechanical washing or by antimicrobial efficacy of hypochlorous acid, could reduce patient contagion, prevent the occurrence of more severe symptoms and improve the course of the disease at an early stage, also reducing the likelihood of virus transmission to other persons’.
"If Sars-Cov-2 is less present in the upper respiratory tract, the likelihood of it falling down the lower airways and damaging the lungs, as well as the risk of local injury to the olfactory nerve routes, which is responsible for the loss of the smell related to Covid-19, is reduced.
The spray, if used at the initial stages of the infection or in the event of exposure to the risk of infection, could therefore reduce the likelihood of contagion, clinical deterioration and transmissibility of the infection.’
Mondobiotech Holding AG Basel (RLFTF) Stock Research Links
$MJ
